Skip to main content
SpringerLink
Log in

The safety and efficacy of a novel method for treatment of HSIL

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

To investigate the efficacy and safety of Nr-CWS on treatment of cervical HSIL.

Method

In this observational study, 16 patients were treated with Nr-CWS 1 time every 2 days for 6 times as one-course group (OC group), the other 184 patients were treated with Nr-CWS 1 time every 2 days for 12 times between 2 menstruations as two-course group (TC group). The medical information including age, HPV assay, vaginal–cervical cytology, and the pathological result of biopsy before and after treatment was collected. All patients were followed up at least twice after treatment. The LEEP was performed once the patients with persistent HR-HPV infection and/or abnormal TCT after the second follow-up.

Results

The cytology remission rate of cervical HSIL in OC and TC group was 100.0% and 87.8%, respectively, which were significant higher than the control (25.0%) with the P value of 2.00 × 10–3 and 2.06 × 10–4. Furthermore, HPV clearance rate was 87.5% and 70.2% in OC and TC group, respectively, which were significant higher than control (32.4%) with the P value of 2.74 × 10−4 and 2.18 × 10–5, respectively. Moreover, the more severe of cytology, the worse effect of HPV clearance for the HPV remission was 75.4%, 68.3%, 67.4%, 65.6% and 64.3% in the negative, LSIL, ASC-US, ASC-H, and HSIL group. 12 patients underwent LEEP after Nr-CWS treatment, 9 (75%) had persistent HSIL and 44.4% cases were found HSIL lesion in the cervical canal. There was no serious adverse reaction observed during treatment and follow-up, four patients were pregnant after treatment and no adverse pregnancy outcomes were observed.

Conclusion

Nr-CWS is an effective and safe drug for treatment of cervical HSIL for Chinese women, especially for cases without lesions in cervical canal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  Google Scholar 

  2. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006) HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 208(2):152–164. https://doi.org/10.1002/path.1866

    Article  CAS  PubMed  Google Scholar 

  3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet (London, England) 370(9590):890–907. https://doi.org/10.1016/s0140-6736(07)61416-0

    Article  CAS  Google Scholar 

  4. Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet (London, England) 393(10167):169–182. https://doi.org/10.1016/s0140-6736(18)32470-x

    Article  Google Scholar 

  5. Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J (2016) Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ (Clinical research ed) 355:i4924. https://doi.org/10.1136/bmj.i4924

    Article  Google Scholar 

  6. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A (2017) Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet (London, England) 390(10108):2143–2159. https://doi.org/10.1016/s0140-6736(17)31821-4

    Article  CAS  Google Scholar 

  7. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M (2019) Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ (Clinical research ed) 365:l1161. https://doi.org/10.1136/bmj.l1161

    Article  Google Scholar 

  8. Jing L, Dan W, Zhunan L, Ying X, Yi C (2018) Residual lesions in uterine specimens after loop electrosurgical excision procedure in patients with CIN. Arch Gynecol Obstet 298(4):805–812. https://doi.org/10.1007/s00404-018-4881-7

    Article  PubMed  Google Scholar 

  9. Fujisawa T, Yamaguchi Y (1996) Postoperative immunostimulation after complete resection improves survival of patients with stage I nonsmall cell lung carcinoma. Cancer 78(9):1892–1898. https://doi.org/10.1002/(sici)1097-0142(19961101)78:9%3c1892::aid-cncr8%3e3.3.co;2-u

    Article  CAS  PubMed  Google Scholar 

  10. Zhao J, Du HJ, Liao QP (2007) Effect of Nocardia rubra cell wall skeleton on the growth of HeLa cell line infected with HPV. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 21(1):20–22

    PubMed  Google Scholar 

  11. Zhao J, Zhan SB, Li XQ, Zhou L, Yang YJ, Liao QP (2007) Effect of Nocardia rubra cell wall skeleton (Nr-CWS) on oncogenicity of TC-1 cells and anti-human papillomavirus effect of Nr-CWS in lower genital tract of women. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 21(4):340–342

    CAS  PubMed  Google Scholar 

  12. Smith JH (2002) Bethesda 2001. Cytopathol Off J Br Soc Clin Cytol 13(1):4–10

    Article  CAS  Google Scholar 

  13. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer (IARC), Lyon

    Google Scholar 

  14. Fu Y, Bao Y, Hui Y, Gao X, Yang M, Chang J (2016) Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection. Photodiagn Photodyn Ther 13:29–33. https://doi.org/10.1016/j.pdpdt.2015.12.004

    Article  CAS  Google Scholar 

  15. Case AS, Rocconi RP, Straughn JM, Wang W, Roark K, Waltman EE, Huh WK (2006) Cervical intraepithelial neoplasia in adolescent women: incidence and treatment outcomes. Obstet Gynecol 108(6):1369–1374. https://doi.org/10.1097/01.aog.0000245448.19446.81

    Article  PubMed  Google Scholar 

  16. Kucera E, Sliutz G, Czerwenka K, Breitenecker G, Leodolter S, Reinthaller A (2001) Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone? Eur J Obstet Gynecol Reprod Biol 100(1):72–76. https://doi.org/10.1016/s0301-2115(01)00457-2

    Article  CAS  PubMed  Google Scholar 

  17. Lörincz AT, Richart RM (2003) Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 127(8):959–968. https://doi.org/10.1043/1543-2165(2003)127%3c959:hpdtaa%3e2.0.co;2

    Article  PubMed  Google Scholar 

  18. Dong B, Sun P, Ruan G, Huang W, Mao X, Kang Y, Pan D, Lin F (2018) Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case–control study. Cancer Manag Res 10:4839–4851. https://doi.org/10.2147/cmar.s179724

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kang WD, Choi HS, Kim SM (2013) Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 130(2):264–268. https://doi.org/10.1016/j.ygyno.2013.04.050

    Article  CAS  PubMed  Google Scholar 

  20. Chang DY, Song SH, You S, Lee J, Kim J, Racanelli V, Son H, Shin EC (2014) Programmed death-1 (PD-1)-dependent functional impairment of CD4(+) T cells in recurrent genital papilloma. Clin Exp Med 14(3):305–313. https://doi.org/10.1007/s10238-013-0245-6

    Article  CAS  PubMed  Google Scholar 

  21. Wang G, Wu J, Miao M, Dou H, Nan N, Shi M, Yu G, Shan F (2017) Nocardia rubra cell-wall skeleton promotes CD4 T cell activation and drives Th1 immune response. Int J Biol Macromol 101:398–407. https://doi.org/10.1016/j.ijbiomac.2017.03.060

    Article  CAS  PubMed  Google Scholar 

  22. Meng Y, Sun J, Wang X, Ma Y, Kong C, Zhang G, Dou H, Nan N, Shi M, Yu T, Piao H (2019) The biological macromolecule Nocardia rubra cell-wall skeleton as an avenue for cell-based immunotherapy. J Cell Physiol. https://doi.org/10.1002/jcp.28182

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Jian Zhao and Hui Feng contributed equally to this work.

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Peking University First Hospital, Xicheng District, Beijing, 100034, China

    Jian Zhao, Hui Feng & Yimin Cui

  2. Office of International Cooperation, Peking University Health Science Center, Beijing, 100191, China

    Tingting Wang & Xiaocong Pang

  3. Department of Pharmacy, Peking University First Hospital, Xicheng District, Beijing, 100034, China

    Yingfang Zhou

Authors
  1. Jian Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tingting Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaocong Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yingfang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yimin Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YZ and YC designed experiments. HF and TW carried out experiments. XP analyzed experimental results. JZ wrote the manuscript.

Corresponding authors

Correspondence to Yingfang Zhou or Yimin Cui.

Ethics declarations

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in the manuscript entitled, “The safety and efficacy of a novel method for treatment of HSIL”.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, J., Feng, H., Wang, T. et al. The safety and efficacy of a novel method for treatment of HSIL. Arch Gynecol Obstet 304, 1291–1298 (2021). https://doi.org/10.1007/s00404-021-06047-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-021-06047-1

Keywords

Search

Navigation